Literature DB >> 17660033

Monitoring biological action of rapamycin in renal transplantation.

Domenica Leogrande1, Annalisa Teutonico, Elena Ranieri, Marilisa Saldarelli, Loreto Gesualdo, F Paolo Schena, Salvatore Di Paolo.   

Abstract

BACKGROUND: Inhibition of P70S6 kinase (P70(S6K)) phosphorylation in activated T cells is 1 of the major mechanisms by which rapamycin exerts its immunosuppressive action. STUDY
DESIGN: Observational cohort study. SETTINGS & PARTICIPANTS: 2 different groups of kidney transplant recipients at a single center: 30 transplant recipients converted from mycophenolic acid and low-dose prednisone plus cyclosporine A to mycophenolic acid and low-dose prednisone plus rapamycin therapy for chronic allograft nephropathy (group 1) and 16 recipients of suboptimal organs converted from tacrolimus plus rapamycin to rapamycin therapy alone after 3 months (group 2). PREDICTOR: Exposure to rapamycin therapy and rapamycin trough levels. OUTCOMES & MEASUREMENTS: Basal and stimulated phosphorylation of P70(S6K) was measured by using Western blotting in patients' peripheral-blood mononuclear cells before and 6 to 11 months after conversion to rapamycin-based therapy. Kinase activation was attained in vivo by means of intravenous insulin injection.
RESULTS: The potency of rapamycin inhibition of P70(S6K) phosphorylation varied among patients (RAPA blood concentration required to achieve 50% inhibition of P70(S6K) activation for mitogen-activated kinase, 3.14 to 12.14 ng/mL) and failed to correlate with drug trough levels. The combination of tacrolimus and rapamycin limited the inhibitory effect of the latter drug on P70(S6K) activation. LIMITATIONS: Need for additional studies exploring the relationship between P70(S6K) activity and kidney graft outcome. Exclusion of patients with diabetes.
CONCLUSIONS: Long-term rapamycin treatment inhibits P70(S6K) phosphorylation in peripheral-blood mononuclear cells without significant correlation with rapamycin trough levels. By measuring in vivo the biological action of rapamycin, the assay may provide potentially relevant information for the clinical management of rapamycin-treated patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660033     DOI: 10.1053/j.ajkd.2007.05.002

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  2 in total

Review 1.  A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Authors:  Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

2.  P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.

Authors:  Jun-Yu Wang; Hua Fan
Journal:  Chin Med J (Engl)       Date:  2015-03-05       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.